8 research outputs found
Dyslipidaemia in early rheumatoid arthritis patients is common and not influenced by two years of effective DMARD therapy. The Opera study.
Full text linkPatterns of MRI bone erosion in rheumatoid arthritis. Which bones are most frequently involved and show most change?
Full text link10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis:Baseline Predictors of Functional and Radiographic Outcomes
Full text linkRadiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial
Full text linkRemission rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA).
Full text linkAdalimumab added to Methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis - An investigator-initiated randomized, controlled, double-blinded study.
Full text link
